W
Wendie Hopkins
Researcher at Ludwig Institute for Cancer Research
Publications - 21
Citations - 2075
Wendie Hopkins is an academic researcher from Ludwig Institute for Cancer Research. The author has contributed to research in topics: Antigen & Epitope. The author has an hindex of 17, co-authored 21 publications receiving 1967 citations.
Papers
More filters
Journal ArticleDOI
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Ian D. Davis,Weisan Chen,Heather Jackson,Phillip Parente,Phillip Parente,Mark Shackleton,Mark Shackleton,Mark Shackleton,Wendie Hopkins,Qiyuan Chen,Nektaria Dimopoulos,Tina Luke,Roger Murphy,Andrew M. Scott,Andrew M. Scott,Eugene Maraskovsky,Grant A. McArthur,Duncan MacGregor,Sue Sturrock,Tsin Yee Tai,Simon Green,Andrew Cuthbertson,Darryl W. Maher,Lena Miloradovic,Susan V. Mitchell,Gerd Ritter,Achim A. Jungbluth,Yao-Tseng Chen,Yao-Tseng Chen,Sacha Gnjatic,Eric W. Hoffman,Lloyd J. Old,Jonathan Cebon,Jonathan Cebon +33 more
TL;DR: In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone, suggesting the vaccine is safe and highly potent immunologically.
Journal Article
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Andrew M. Scott,G. A. Wiseman,Sydney Welt,Alex A. Adjei,Fook-Thean Lee,Wendie Hopkins,Chaitan R. Divgi,Lorelei H Hanson,Paul Mitchell,Denise N. Gansen,Steven M. Larson,James N. Ingle,Eric W. Hoffman,Paul Tanswell,Gerd Ritter,Leonard Cohen,Peter Bette,Lisa Arvay,Andree Amelsberg,Dan Vlock,Wolfgang J. Rettig,Lloyd J. Old +21 more
TL;DR: Repeat infusions of the humanized anti-FAP antibody sibrotuzumab can be administered safely to patients with advanced FAP-positive cancer, and a maximum tolerated dose was not reached.
Journal ArticleDOI
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
Andrew M. Scott,Fook-Thean Lee,Niall C. Tebbutt,R. A. Herbertson,S Gill,Zhanqi Liu,Effie Skrinos,Carmel Murone,T. Saunder,Bridget Chappell,Anthony T. Papenfuss,A. M. T. Poon,Wendie Hopkins,Fiona E Smyth,Duncan MacGregor,Lawrence M Cher,Achim A. Jungbluth,Gerd Ritter,Martin W. Brechbiel,Roger Murphy,Antony W. Burgess,Eric W. Hoffman,Terrance Grant Johns,Lloyd J. Old +23 more
TL;DR: The present clinical study was designed to examine the in vivo specificity of a chimeric form of mAb 806 (ch806) in a tumor targeting/biodistribution/pharmacokinetic analysis in patients with diverse tumor types, and showed excellent targeting of tumor sites in all patients, no evidence of normal tissue uptake, and no significant toxicity.
Journal ArticleDOI
A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake
Andrew M. Scott,Fook-Thean Lee,Robert M Jones,Wendie Hopkins,Duncan MacGregor,Jonathon Cebon,A. Hannah,Geoffrey Chong,Paul U,Anthony T. Papenfuss,Angela Rigopoulos,Susan Sturrock,Roger Murphy,Veronika Wirth,Carmel Murone,Fiona E Smyth,Simon Knight,Sydney Welt,Gerd Ritter,Richards Elizabeth C,Edouard C. Nice,Anthony W Burgess,Lloyd J. Old +22 more
TL;DR: HuA33 shows selective and rapid localization to colorectal carcinoma in vivo and penetrates to the center of large necrotic tumors, and colon elimination half-life of huA 33 is equivalent to basal colonocyte turnover.
Journal Article
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
Mark Shackleton,Ian D. Davis,Wendie Hopkins,Heather Jackson,Nektaria Dimopoulos,Tsin Yee Tai,Qiyuan Chen,Phillip Parente,Michael Jefford,Kelly-Anne Masterman,Dania Caron,Weisan Chen,Eugene Maraskovsky,Jonathan Cebon +13 more
TL;DR: In vivo maturation of FL-generated DCs using imiquimod may increase immune responses to tumor antigens, and in vivo treatment of melanoma patients with metastatic or high-risk resected melanoma with FL was generally safe and well tolerated, although some patients developed clinically significant toxicities related to FL.